Clinical Trial Update: Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study [Phase 3]

View source ↗

Summary

Phase 3 randomized trial of DAS181 for lower respiratory tract Parainfluenza infection in immunocompromised subjects, with a sub-study for COVID-19; currently r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lower Respiratory Tract Infection
• Parainfluenza Virus Infection

Drugs mentioned

• DAS-181

Snippet

Sponsor: Ansun Biopharma, Inc. | Conditions: Lower Respiratory Tract Infection, Parainfluenza | Phase 3 | Status: RECRUITING